Home » Authors » Douglas Merrill

Articles by Douglas Merrill

Financial Forum Attendees View Future With Cautious Optimism

June 23, 2004

By Douglas Merrill

Icatibant Helps Jerini Raise EUR31M In Series B Financing

June 23, 2004

By Douglas Merrill

Icatibant Helps Jerini Raise EUR31M In Series B Financing

June 23, 2004

By Douglas Merrill

Financial Forum Attendees View Future With Cautious Optimism

June 23, 2004

By Douglas Merrill

Wilex Initiates Phase III Study Of Renal-Cell Carcinoma Drug

June 16, 2004

By Douglas Merrill

Wilex Initiates Phase III Study Of Renal-Cell Carcinoma Drug

June 16, 2004

By Douglas Merrill

Phase II Results Open Pathway For Paion's EUR9.8M Fourth Round

May 26, 2004

By Douglas Merrill

Phase II Results Open Pathway For Paion's EUR9.8M Fourth Round

May 26, 2004

By Douglas Merrill

DeveloGen Finalizes Merger With Peptor, Raises EUR19M

May 19, 2004

By Douglas Merrill

DeveloGen Finalizes Merger With Peptor, Raises EUR19M

May 19, 2004

By Douglas Merrill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...